Results 251 to 260 of about 169,027 (313)

Is Zebrafish a Good Model for the Alpha‐Gal Syndrome?

The FASEB Journal, Volume 39, Issue 9, 15 May 2025.
ABSTRACT The alpha‐Gal syndrome (AGS) is an underdiagnosed tick‐borne allergy characterized by both immediate and delayed IgE‐mediated anaphylactic reactions to the galactose‐alpha‐1,3‐galactose (alpha‐Gal) epitope. Common manifestations include gastrointestinal, cutaneous, and respiratory symptoms appearing 2–6 h after the consumption of mammalian ...
Rita Vaz‐Rodrigues, José de la Fuente
wiley   +1 more source

The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications. [PDF]

Biomark Res
Hodges A, Dubuque R, Chen SH, Pan PY.
europepmc   +1 more source

A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation

American Journal of Hematology, Volume 100, Issue 5, Page 797-812, May 2025.
ABSTRACT Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by ...
Chia‐Yu Wang, Emiliano Melgar‐Bermudez, Diana Welch, Kevin B. Dagbay, Seemana Bhattacharya, Evan Lema, Tyler Daman, Olivia Sierra, Radina Todorova, Papa Makhtar Drame, Rosa Grenha, Ffolliott M. Fisher, Dena Grayson, Lorena Lerner, Samuel M. Cadena, Jasbir Seehra, Jennifer Lachey   +16 more
wiley   +1 more source

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies. [PDF]

Kidney Int Rep
Teisseyre M, Allinovi M, Audard V, Cremoni M, Belvederi G, Karamé A, Accinno M, Duquesne J, Sharma V, Fernandez C, Zorzi K, El Maï M, Brglez V, Benzaken S, Esnault VLM, Vultaggio A, Kohli HS, Ramachandran R, Cirami CL, Seitz-Polski B.   +19 more
europepmc   +1 more source

Lecanemab‐Associated Amyloid‐β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease

Annals of Neurology, Volume 97, Issue 5, Page 993-1006, May 2025.
Objective The Clarity AD phase III trial showed that lecanemab reduced amyloid markers in early Alzheimer's disease (AD) and resulted in less decline on measures of cognition and function than placebo. Herein, we aimed to characterize amyloid‐β (Aβ) protofibril (PF) captured by lecanemab in human cerebrospinal fluid (CSF) from living participants with ...
Moeko Noguchi‐Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono   +8 more
wiley   +1 more source

Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab. [PDF]

Biologics
Patra AK, Nayak S, Moharana A, Ojha P, Das SK, Akhtar J, Giri B, Singh S.   +7 more
europepmc   +1 more source

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1352-1360, May 2025.
Abstract The development of humanized IgG1 anti‐amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease‐modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has ...
Amy Bobbins, Miranda Davies, Elizabeth Lynn, Debabrata Roy, Alison Yeomans, Saad A. W. Shakir   +5 more
wiley   +1 more source

Missed opportunities to increase efficiency of monoclonal antibody development using hybridoma technology and mice as the source animal. [PDF]

Front Immunol
Chakravarty E, Dorak MT.
europepmc   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1306-1321, May 2025.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source

Early-Onset Autoimmune Hemolytic Anemia from Pembrolizumab in a Patient with Metastatic Lung Cancer: A Case Report. [PDF]

Am J Case Rep
Adeoye FW, Surandran S, Jaffar N, Serumadar S, Begum G.   +4 more
europepmc   +1 more source